| Dr Colleen Ann Crowe, MD, MPH | |
|
9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 | |
| (414) 805-6469 | |
| Not Available |
| Full Name | Dr Colleen Ann Crowe |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 9200 W Wisconsin Ave, Milwaukee, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003071283 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 53332-020 (Wisconsin) | Primary |
| Entity Name | The Medical College Of Wisconsin Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699720086 PECOS PAC ID: 2668384371 Enrollment ID: O20031120000259 |
News Archive
Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Researchers have found that a class of RNA molecules, previously thought to have no function, may in fact protect sex cells from self-destructing. These findings will be published in the November 17 issue of the journal Cell.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 8 days ago
| Entity Name | Froedtert &the Medical College Of Wisconsin Community Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568787448 PECOS PAC ID: 3678760063 Enrollment ID: O20101210000699 |
News Archive
Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Researchers have found that a class of RNA molecules, previously thought to have no function, may in fact protect sex cells from self-destructing. These findings will be published in the November 17 issue of the journal Cell.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Colleen Ann Crowe, MD, MPH 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-6469 | Dr Colleen Ann Crowe, MD, MPH 9200 W Wisconsin Ave, Milwaukee, WI 53226-3522 Ph: (414) 805-6469 |
News Archive
Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression (TTP) and overall response rates after receiving a combination of DOXIL (doxorubicin HCl liposome injection) and docetaxel as compared to docetaxel alone.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Researchers have found that a class of RNA molecules, previously thought to have no function, may in fact protect sex cells from self-destructing. These findings will be published in the November 17 issue of the journal Cell.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 8 days ago
Natalia Rumas, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2323 N Lake Dr, Milwaukee, WI 53211 Phone: 414-290-6720 Fax: 414-290-6755 | |
Adam C Ankrum, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 111 E Wisconsin Ave, Suite 2000, Milwaukee, WI 53202 Phone: 414-290-6720 Fax: 414-290-6755 | |
Andrea Michelle Kraus, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3237 S 16th St Ste 100, Milwaukee, WI 53215 Phone: 414-647-5203 Fax: 414-858-2236 | |
Lisa Hubbard, CFNP Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5000 W Chambers St, Milwaukee, WI 53210 Phone: 414-447-2000 Fax: 414-874-4393 | |
Mr. Brad A. Johnson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2900 W Oklahoma Ave, Milwaukee, WI 53215 Phone: 414-649-6000 | |
Mckenna Jean Knych, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 9200 W Wisconsin Ave, Milwaukee, WI 53226 Phone: 414-805-6450 Fax: 414-805-6464 |